How has the cutaneous squamous cell carcinoma (cscc) market evolved, and where is it heading next?
The cutaneous squamous cell carcinoma (cSCC) market size has grown strongly in recent years. It will grow from $7.45 billion in 2024 to $7.90 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising prevalence of non-melanoma skin cancers, a growing elderly population, increased exposure to ultraviolet radiation, improved healthcare infrastructure, and the growing use of immunotherapy in oncology.
The cutaneous squamous cell carcinoma (cSCC) market size is expected to see strong growth in the next few years. It will grow to $9.90 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing availability of targeted therapies, higher awareness of skin cancer prevention, expanding medical tourism for cancer treatments, increasing adoption of minimally invasive surgeries, and favorable government initiatives for cancer care. Major trends in the forecast period include advancements in dermatology diagnostics, development of advanced radiotherapy techniques, technological integration in dermatology, innovations in immunotherapy treatments, and advancements in photodynamic therapy.
Get Your Free Sample of The Global Cutaneous Squamous Cell Carcinoma (CSCC) Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21163&type=smp
What are the key drivers behind the rapid expansion of the cutaneous squamous cell carcinoma (cscc) market?
The growing awareness about skin cancer is projected to propel the growth of the cutaneous squamous cell carcinoma (cSCC) market going forward. Skin cancer is the abnormal growth of skin cells, often caused by excessive UV exposure, and can range from harmless to life-threatening. The growing awareness about skin cancer is due to increased public health campaigns, improved access to information, and a rising emphasis on early detection and prevention, leading to greater demand for diagnostic and treatment solutions. Cutaneous squamous cell carcinoma (cSCC) is useful for advancing skin cancer care by enabling targeted therapies, improving diagnosis, and enhancing patient outcomes, ultimately supporting better disease management. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, there were 104,930 reported cases of skin cancer in 2023, reflecting a 3.2% increase from the 108,270 cases reported in 2022. Therefore, growing awareness about skin cancer will fuel growth in the cutaneous squamous cell carcinoma (cSCC) market.
What is the segmentation for the cutaneous squamous cell carcinoma (cscc) market?
The cutaneous squamous cell carcinoma (CSCC) market covered in this report is segmented –
1) By Treatment: Surgical Treatment, Non-Surgical Treatment
2) By Diagnosis: Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Biopsy
3) By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Other Applications
Subsegments:
1) By Surgical Treatment: Excisional Surgery, Mohs Micrographic Surgery, Curettage And Electrodessication
2) By Non-Surgical Treatment: Radiation Therapy, Cryotherapy, Photodynamic Therapy, Topical Therapies, Systemic Therapies
Order your report now for swift delivery
Who are the most influential companies in the cutaneous squamous cell carcinoma (cscc) market?
Major companies operating in the cutaneous squamous cell carcinoma (CSCC) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, 3M Company, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Hikma Pharmaceuticals plc, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., CureVac N.V., Vidac Pharma Inc.
What are the most influential trends expected to drive the cutaneous squamous cell carcinoma (cscc) market forward?
Major companies operating in the cutaneous squamous cell carcinoma (cSCC) market are focusing on advancements in immuno-oncology therapies, such as PD-L1 inhibitors and targeted therapies, to improve patient outcomes and provide effective solutions for managing advanced skin cancer. PD-L1, or programmed death-ligand 1, is a protein that suppresses the immune response by binding to PD-1 receptors on T-cells, helping cancer cells evade immune detection. For instance, in December 2024, Checkpoint Therapeutics Inc., a US-based biotech company, received the FDA approval for Unloxcyt (cosibelimab-ipdl). The innovation lies in its ability to block PD-L1, enhancing the immune system’s ability to fight cancer while offering a safer and more effective treatment option. Additionally, its dual mechanisms of action provide a promising approach for managing advanced cutaneous squamous cell carcinoma (cSCC). The approval was based on results from the CK-301-101 trial, which demonstrated clinically meaningful objective response rates and durable responses in patients with advanced cSCC.
What are the major regional insights for the cutaneous squamous cell carcinoma (cscc) market, and which region holds the top position?
North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous squamous cell carcinoma (CSCC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cutaneous Squamous Cell Carcinoma (CSCC) Market Report 2025 Offer?
The cutaneous squamous cell carcinoma (cscc) market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cutaneous squamous cell carcinoma (cSCC) is a type of skin cancer that develops in the squamous cells of the skin’s outer layer. It typically occurs in sun-exposed areas and can range from localized lesions to more aggressive forms that may spread to other parts of the body.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21163
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
